What is xgeva used for?

Treatment for Bone Metastases and Tumors

Xgeva, a medication developed by Amgen, is used to prevent skeletal fractures caused by bone metastases from various cancers, including breast, lung, and prostate cancer [1]. Bone metastases are tumors that have spread from their original site to the bones, leading to bone destruction and an increased risk of fractures.

How Xgeva Works

Xgeva is a RANKL inhibitor, which means it works by blocking the action of a protein called RANKL (Receptor Activator of NF-kB Ligand) that helps cancer cells spread to bone. By inhibiting RANKL, Xgeva reduces the formation of new bone metastases and slows down the progression of existing bone metastases.

Clinical Trials and Approval

Xgeva was approved by the FDA in 2010 for the prevention of skeletal-related events (SREs) such as fractures, radiation therapy to bone, surgery to bone, and spinal cord compression in patients with bone metastases from solid tumors [2]. The approval was based on data from clinical trials that showed Xgeva reduced the risk of SREs by 33% compared to a placebo.

Use in Other Conditions

Xgeva is also used to treat giant cell tumor of bone, a rare type of bone tumor that can cause bone pain and limited mobility [3]. Additionally, Xgeva has been studied as a treatment for osteoporosis, a condition characterized by weak and brittle bones [4].

Side Effects and Warnings

Common side effects of Xgeva include fatigue, nausea, dizziness, and bone pain. Patients taking Xgeva should inform their doctor if they experience any unusual symptoms, such as difficulty swallowing or speaking, as these can be signs of an allergic reaction [5].

Patient Concerns

While Xgeva can be an effective treatment for bone metastases and other bone-related conditions, patients should be aware that it may increase the risk of osteonecrosis (bone death) of the jaw, particularly if they have a history of dental procedures or use of dental appliances [6].

Patent Expiration

The patent for Xgeva is set to expire in 2029, which may lead to the development of generics and biosimilars that can offer competing alternatives to patients [7].

Sources

[1] Amgen. (2022). Xgeva Prescribing Information.

[2] FDA. (2010). FDA Approves Xgeva to Prevent Skeletal-Related Events in Patients with Solid Tumors.

[3] Amgen. (2022). Xgeva Uses and Benefits.

[4] J Bone Miner Res. (2018). RANKL inhibition in osteoporosis.

[5] FDA. (2022). Xgeva Safety and Efficacy.

[6] Oncologist. (2014). Osteonecrosis of the jaw associated with RANKL inhibitors.

[7] DrugPatentWatch.com. (2022). Xgeva Patent Expiration Date.